register

News & Trends - Pharmaceuticals

AbbVie’s $3.9 billion oncology collaboration with Genmab

Health Industry Hub | June 15, 2020 |

Pharma News: AbbVie and Genmab entered a collaboration agreement to jointly develop and commercialise three of Genmab’s early-stage antibody product candidates and future differentiated antibody therapeutics for cancer.

The companies will partner to develop Genmab’s next-generation bispecific antibody programs, epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4. The collaboration combines Genmab’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with AbbVie’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in haematological cancers.

Genmab already has a proven history of successful collaborations with pharma companies that have generated marketed products, including Novartis’ Arzerra (ofatumumab) for chronic lymphocytic leukaemia which is also in late-stage development as a multiple sclerosis therapy, and Johnson & Johnson multiple myeloma therapy Darzalex (daratumumab), a multi-billion dollar product in intravenous form and new subcutaneous formulation.

You may also like Key recommendations for data access to modernise Australia’s healthcare system post COVID-19 – Podcast

“This transformative collaboration will allow us to accelerate, broaden and maximise the development of some of our promising early-stage bispecific antibodies, including epcoritamab, with the ultimate goal of bringing these potential therapies much faster to cancer patients,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “The announcement marks the beginning of a new journey for Genmab that combines our world-class knowledge in antibody biology and deep expertise in truly innovative next-generation antibody technology platforms, with AbbVie’s R&D prowess and their leadership position in haematological cancers.”

“Epcoritamab is a strong fit for our robust haematological oncology franchise,” said Michael Severino, M.D., Vice Chairman and President, AbbVie. “By combining the strengths of our two organisations, we can advance the treatment landscape for patients battling cancer.”

Register & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.